Suppr超能文献

性别肯定激素疗法对肾功能指标的影响:系统评价和荟萃分析。

The Effect of Gender-Affirming Hormone Therapy on Measures of Kidney Function: A Systematic Review and Meta-Analysis.

机构信息

Chronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, Manitoba, Canada.

University of Manitoba, Winnipeg, Manitoba, Canada.

出版信息

Clin J Am Soc Nephrol. 2022 Sep;17(9):1305-1315. doi: 10.2215/CJN.01890222. Epub 2022 Aug 16.

Abstract

BACKGROUND AND OBJECTIVES

Gender-affirming hormone therapy modifies body composition and lean muscle mass in transgender persons. We sought to characterize the change in serum creatinine, other kidney function biomarkers, and GFR in transgender persons initiating masculinizing and feminizing gender-affirming hormone therapy.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We searched PubMed, EMBASE, the Cochrane Library, and ClinicalTrials.gov from inception to September 16, 2020 for randomized controlled trials, observational studies, and case series that evaluated the change in serum creatinine, other kidney function biomarkers, and GFR before and after the initiation of gender-affirming hormone therapy in adult transgender persons. Two reviewers independently screened and abstracted data, and disagreements were resolved by a third reviewer. A random effects meta-analysis was performed to determine the change in outcomes over follow-up of 3, 6, and 12 months.

RESULTS

Of the 4758 eligible studies, 26 met the inclusion criteria, including nine studies that recruited 488 transgender men and 593 women in which data were meta-analyzed. There was heterogeneity in study design, populations, gender-affirming hormone therapy routes, and dosing. At 12 months after initiating gender-affirming hormone therapy, serum creatinine increased by 0.15 mg/dl (95% confidence interval, 0.00 to 0.29) in 370 transgender men and decreased by -0.05 mg/dl (95% confidence interval, -0.16 to 0.05) in 361 transgender women. No study reported the effect of gender-affirming hormone therapy on albuminuria, proteinuria, cystatin C, or measured GFR.

CONCLUSIONS

Gender-affirming hormone therapy increases serum creatinine in transgender men and does not affect serum creatinine in transgender women. The effect on gender-affirming hormone therapy on other kidney function biomarkers and measured GFR is unknown.

CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER

Change in Kidney Function Biomarkers in Transgender Persons on Gender Affirmation Hormone Therapy-A Systematic Review and Meta-Analysis, CRD42020214248.

摘要

背景与目的

性别肯定激素治疗改变了跨性别者的身体成分和瘦肌肉质量。我们旨在描述开始男性化和女性化性别肯定激素治疗的跨性别者的血清肌酐、其他肾功能生物标志物和肾小球滤过率的变化。

设计、设置、参与者和测量方法:我们从 2020 年 9 月 16 日开始在 PubMed、EMBASE、Cochrane 图书馆和 ClinicalTrials.gov 上搜索了评估成年跨性别者开始性别肯定激素治疗前后血清肌酐、其他肾功能生物标志物和 GFR 变化的随机对照试验、观察性研究和病例系列。两位评审员独立筛选和提取数据,分歧由第三位评审员解决。进行随机效应荟萃分析以确定 3、6 和 12 个月随访期间结局的变化。

结果

在 4758 项合格研究中,有 26 项符合纳入标准,其中包括 9 项研究招募了 488 名跨性别男性和 593 名女性,对这些数据进行了荟萃分析。研究设计、人群、性别肯定激素治疗途径和剂量存在异质性。在开始性别肯定激素治疗后 12 个月,370 名跨性别男性的血清肌酐增加了 0.15mg/dl(95%置信区间,0.00 至 0.29),而 361 名跨性别女性的血清肌酐减少了 0.05mg/dl(95%置信区间,-0.16 至 0.05)。没有研究报告性别肯定激素治疗对蛋白尿、蛋白尿、胱抑素 C 或测量的肾小球滤过率的影响。

结论

性别肯定激素治疗增加了跨性别男性的血清肌酐,对跨性别女性的血清肌酐没有影响。性别肯定激素治疗对其他肾功能生物标志物和测量的肾小球滤过率的影响尚不清楚。

临床试验注册号和名称

接受性别肯定激素治疗的跨性别者的肾功能生物标志物变化-系统评价和荟萃分析,CRD42020214248。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f60b/9625103/ebebf9399775/CJN.01890222absf1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验